US 12,214,003 B2
Composition for inducing proliferation or accumulation of regulatory T cells
Kenya Honda, Tokyo (JP); Koji Atarashi, Tokyo (JP); Kikuji Itoh, Tokyo (JP); and Takeshi Tanoue, Tokyo (JP)
Assigned to The University of Tokyo, Tokyo (JP)
Filed by The University of Tokyo, Tokyo (JP)
Filed on May 28, 2024, as Appl. No. 18/676,470.
Application 18/676,470 is a continuation of application No. 17/371,692, filed on Jul. 9, 2021.
Application 17/371,692 is a continuation of application No. 16/780,116, filed on Feb. 3, 2020, granted, now 11,090,343.
Application 16/780,116 is a continuation of application No. 16/425,030, filed on May 29, 2019, granted, now 10,555,978.
Application 16/425,030 is a continuation of application No. 16/389,380, filed on Apr. 19, 2019, granted, now 10,588,925.
Application 16/389,380 is a continuation of application No. 16/171,558, filed on Oct. 26, 2018, granted, now 10,328,108.
Application 16/171,558 is a continuation of application No. 16/117,054, filed on Aug. 30, 2018, granted, now 10,322,150.
Application 16/117,054 is a continuation of application No. 15/730,203, filed on Oct. 11, 2017, granted, now 10,092,603.
Application 15/730,203 is a continuation of application No. 15/216,015, filed on Jul. 21, 2016, granted, now 9,801,933.
Application 15/216,015 is a continuation of application No. 14/492,850, filed on Sep. 22, 2014, granted, now 9,433,652.
Application 14/492,850 is a continuation of application No. 13/701,467, abandoned, previously published as PCT/JP2011/063302, filed on Jun. 3, 2011.
Claims priority of application No. 2010-129134 (JP), filed on Jun. 4, 2010; and application No. PCT/JP2010/071746 (WO), filed on Dec. 3, 2010.
Prior Publication US 2024/0307462 A1, Sep. 19, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/742 (2015.01); A01K 67/0275 (2024.01); A61K 9/00 (2006.01); A61K 9/48 (2006.01); A61K 35/74 (2015.01); A61K 39/00 (2006.01); A61K 39/08 (2006.01); A61K 39/39 (2006.01); A61K 45/00 (2006.01); A61K 45/06 (2006.01); C12Q 1/689 (2018.01); G01N 33/50 (2006.01); A61K 35/00 (2006.01)
CPC A61K 35/742 (2013.01) [A01K 67/0275 (2013.01); A61K 9/0053 (2013.01); A61K 9/48 (2013.01); A61K 35/74 (2013.01); A61K 39/0008 (2013.01); A61K 39/08 (2013.01); A61K 39/39 (2013.01); A61K 45/00 (2013.01); A61K 45/06 (2013.01); C12Q 1/689 (2013.01); G01N 33/505 (2013.01); A01K 2267/0325 (2013.01); A61K 35/00 (2013.01); A61K 2039/52 (2013.01); A61K 2039/542 (2013.01); A61K 2039/55594 (2013.01); A61K 2039/57 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/33 (2013.01); G01N 2500/10 (2013.01)] 9 Claims
 
1. A pharmaceutical composition comprising a spore-forming fraction of human fecal matter;
wherein the pharmaceutical composition is formulated for oral administration;
wherein the spore-forming fraction of human fecal matter in the pharmaceutical composition has been obtained by enriching human fecal matter for a population of spore-forming bacteria therein and comprises two or more bacterial strains; and
wherein the spore-forming fraction of human fecal matter in the pharmaceutical composition induces proliferation and/or accumulation of regulatory T cells and wherein the pharmaceutical composition is in the form of a capsule.